Medical grade heart attack detection

always with the patient
More than 18 million people in the US have Coronary Artery Disease.
Every 40 seconds someone in the US has a heart attack, or myocardial infarction (MI).1

Patients often second-guess
their heart attack symptoms

Unfortunately, there is no way for patients to tell if the symptoms they are experiencing are due to an MI. As a result, patients often ignore symptoms and delay seeking care, which leads to worse outcomes and increased mortality.
Heart Icon
Denial
Heart Icon
Procrastination
Heart Icon
Embarrassment
Heart Icon
Crowded ER
Heart Icon
Self-Diagnosis
Heart Icon
Copayment
Graph 40 percent
40% increased mortality rate2
for an average wait of 3-4 hours after symptoms begin
Yet the only other option is to go to the ER
Chest pain is the #2 most common reason for an ER visit
Chest pain is the second most common reason for an ER visit, yet fewer than 20% of chest pain ER visits result in a diagnosis of a life-threatening condition.3,4 These unnecessary ER visits lead to over $10B in unnecessary healthcare expenditures.5,6
82%
of chest pain ER visits
are unnecessary
$10 billion in cost to the US healthcare system.
Cost to the healthcare
system annually
Current telemedicine is fundamentally limited in its ability to detect heart attacks without a physician and medical quality ECG system in the patient's hands

HeartBeam provides a
personal, portable, and easy-to-use
heart attack detection solution*

HeartBeam provides a
personal, portable, and easy-to-use heart attack detection solution*

Always with the patient
Designed for heart attack detection
Full cardiovascular disease diagnostic
(12 lead capable)
With patient at time of event
Powerful diagnostic suggestion
Uses patient’s own baseline
HeartBeam has developed a system that can be used by patients at home to help their physicians assess whether chest pain is the result of an MI.

For the first time outside of a medical setting, physicians can determine with a patient-friendly device if chest pains are due to a heart attack.
HeartBeam product

HeartBeam AIMIGo™ Technology

HeartBeam AIMI™ and HeartBeam AIMIGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies.

HeartBeam offers a complete
solution for cardiovascular
‍patients and their physicians*

Learn more
smartphone app icon

Smartphone Application

Simple and intuitive patient and user interface
arrow
3D vector collection device

3D Vector Collection Device

Patient places credit card size device on chest for 30 sec signal recording
arrow
heartbeam cloud

Heartbeam Cloud

Diagnostic suggestion & synthesized 12-lead ECG overlaid with baseline
arrow
physician portal

Physician Portal

Physician views 12-lead ECG & diagnostic suggestion. Directs patient
senior using smartphonedoctor on tablet

HeartBeam is designed to deliver enhanced MI detection for millions of patients*

high risk patients with previous MI
High risk patients with previous MI
8 million
patients in the US
Frequent false alarm visitors
Frequent
"false alarm"
ER visitors
+1 million
frequent low-risk ER visits
discharge patients after CV interventions
Patients after cardiovascular interventions
1 million
heart attack interventions

HeartBeam is designed to deliver enhanced MI detection for
‍millions of patients*

Tap each card to learn how HeartBeam helps
high risk patients with previous MI
High CAD Risk / Patients with previous MI
8 million
patients in the US
Frequent false alarm visitors
Frequent "false alarm" ED visitors
+1 million
frequent low-risk ER visits
discharge patients after CV interventions
Patients after cardiovascular interventions
1 million
heart attack interventions
*CAUTION: Product not cleared by the FDA. Limited by United States law to investigational use.

World-class team leading HeartBeam with a
powerful mix of expertise and experience

Learn more about our history
Branislav Vajdic, PhD
CEO & Founder
Branislav Vajdic, PhD
Rob Eno
President
Rob Eno
Rick Brounstein
Chief Financial Officer
Rick Brounstein
Peter Fitzgerald, MD, PhD
Chief Medical Officer
Peter Fitzgerald, MD, PhD
Ken Persen
Chief Technology Officer
Ken Persen
Richa Gujarati
SVP, Product
Richa Gujarati
Deborah Castillo, PhD
VP, Regulatory
Deborah Castillo, PhD
Pooja Chatterjee
VP, Clinical
Pooja Chatterjee
Rich Ferrari
Executive Chairman
Rich Ferrari
Marga Ortigas - Wedekind
Board Member
Marga Ortigas - Wedekind
Wim Elfrink
Board Member
Wim Elfrink
George de Urioste
Board Member
George de Urioste
Kenneth Nelson
Board Member
Kenneth Nelson
Mark Strome
Board Member
Mark Strome
Michael Jaff, DO
Board Member
Michael Jaff, DO

Strong studies demonstrate excellent performance

Harvard Cardiology Research Team conducted 4 studies // 1,210 HeartBeam 3D ECG files collected
HeartBeam 3D ECG has greater accuracy than cardiologists in detecting MI’s
Hides Study
N=186 recordings
HeartBeam 3D ECG has greater accuracy than cardiologists in detecting MI’s
Hides Study
N=186 recordings
HeartBeam 3D ECG has greater accuracy than cardiologists in detecting MI’s
Hides Study
N=186 recordings
HeartBeam 3D ECG has greater accuracy than cardiologists in detecting MI’s
Hides Study
N=186 recordings

Careers at HeartBeam

Current Job Openings
Directors of IT, Santa Clara, CA
Develop IT policies to ensure consistency in standards & leveraging of common systems. Design architecture for complex systems. Develop software with Java Spring Boot, Javascript & Samsung Knox. Work from home authorized. Travel approximately 5% for on-site client visits to ensure implementation of security protocols & standards. National/domestic travel only, limited to the west coast/direct region of the worksite location (Santa Clara, CA). Send resume to: HeartBeam Inc. DBA HeartBeam at npatel@heartbeam.com
*CAUTION: Product not cleared by the FDA. Not available for sale in the United States.
References:
1.  https://www.cdc.gov/heartdisease/facts.htm
2. Saczynski JS, et al. (2008). Am Jrl. Cardiol;102(12): 1589-94
3. Agency for Healthcare Research and Quality, Statistical Brief #174, June 2014
4. Gibson CM et al. J Am Coll Cardiol. 2019 Apr, 73(15) 1919-1927
5. https://www.cdc.gov/nchs/data/nhamcs/web_tables/2020-nhamcs-ed-web-tables-508.pdf
6. https://www.talktomira.com/post/how-much-does-an-er-visit-cost 
‍

HeartBeam provides a medical grade 12 Lead ECG that can be carried in a wallet

Massive and underserved market for remote heart attack detection
High CAD risk/patients with a previous MI
8 million
Patients in the US
heartbeam use graphic
Novel proprietary technology with strong IP protection
Four validation studies led by Harvard Medical School Faculty
FDA 510(k) regulatory path identified
Subscription telehealth business model using existing reimbursement codes